CN106668053A - 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 - Google Patents
王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 Download PDFInfo
- Publication number
- CN106668053A CN106668053A CN201710123392.4A CN201710123392A CN106668053A CN 106668053 A CN106668053 A CN 106668053A CN 201710123392 A CN201710123392 A CN 201710123392A CN 106668053 A CN106668053 A CN 106668053A
- Authority
- CN
- China
- Prior art keywords
- vaccarin
- diabetes
- lipid metabolism
- metabolism disorder
- medicines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GYIKGLVKALOGDP-HLEFUGOVSA-N Vaccarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2OC3=CC(O)=C([C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@H]4[C@@H]([C@@H](O)[C@@H](O)CO4)O)C(O)=C3C(=O)C=2)C=C1 GYIKGLVKALOGDP-HLEFUGOVSA-N 0.000 title claims abstract description 39
- GYIKGLVKALOGDP-DSBKMWIDSA-N Isovitexin 4'-O-glucoside 2''-O-arabinoside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1c1c(O)c2C(=O)C=C(c3ccc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)cc3)Oc2cc1O)[C@@H]1[C@H](O)[C@H](O)[C@H](O)CO1 GYIKGLVKALOGDP-DSBKMWIDSA-N 0.000 title claims abstract description 36
- GYIKGLVKALOGDP-UHFFFAOYSA-N Vaccarin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=C(C4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)CO4)O)C(O)=C3C(=O)C=2)C=C1 GYIKGLVKALOGDP-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 239000003814 drug Substances 0.000 title claims abstract description 18
- 208000017170 Lipid metabolism disease Diseases 0.000 title claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 30
- 229940079593 drug Drugs 0.000 title abstract description 4
- 238000002360 preparation method Methods 0.000 title abstract description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 12
- 239000008103 glucose Substances 0.000 claims abstract description 12
- 230000003178 anti-diabetic effect Effects 0.000 claims description 9
- 239000003472 antidiabetic agent Substances 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 4
- 108010028554 LDL Cholesterol Proteins 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 2
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000007928 intraperitoneal injection Substances 0.000 abstract 1
- 235000016709 nutrition Nutrition 0.000 abstract 1
- 230000035764 nutrition Effects 0.000 abstract 1
- 235000009200 high fat diet Nutrition 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 244000178320 Vaccaria pyramidata Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229930003519 erythroidine Natural products 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- -1 flavone Glycosides Chemical class 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明为制备抗糖尿病糖脂代谢紊乱的王不留行黄酮苷的应用，属中药药物制剂领域。将王不留行黄酮苷应用到抗糖尿病代谢紊乱的药物开发中，以制备更好的治疗糖尿病的方法。本发明发现2型糖尿病小鼠给予腹腔注射王不留行黄酮苷后，空腹血糖水平显著降低，2型糖尿病小鼠血清甘油三酯(TG)、总胆固醇(TCH)，低密度脂蛋白(LDL‑C)水平得到改善，表明王不留行黄酮苷能有效改变糖尿病糖脂代谢紊乱，是治疗糖尿病的一种中药，可以作为新的治疗糖尿病的药物、保健品和营养品进行开发，为治疗糖尿病糖脂代谢紊乱提供了一种新的途径和手段。
Description
技术领域
本发明涉及抗糖尿病糖脂代谢紊乱中药开发，具体设计王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用，属中药药物开发领域。
背景技术
糖尿病是是常见的代谢性疾病之一，也是影响人类健康的非传染性慢性疾病之一。糖尿病的病理特征主要是由于胰岛功能受损，或者靶细胞对胰岛素的敏感性下降引起机体自身糖脂代谢紊乱，临床上根据病因常将糖尿病分为1型糖尿病和2型糖尿病。2014年国际糖尿病联盟调查结果表明全世界约有3.87亿糖尿病患者，预计2035年糖尿病患病人数将达到6亿。中华医学会糖尿病学分会2012年调查显示我国成人糖尿病患病人数达到9240万，并且发病人数逐年攀升，2型糖尿病的发病率超过90％，我国可能已经是世界上糖尿病患病人数最多的国家。无论发展中国家还是发达国家，糖尿病患者的数量都明显增加。随着超重和肥胖青少年人数的不断增多，2型糖尿病可能会发生于青春前期的儿童。糖尿病引发的心、脑、肾、血管、神经系统、眼底病变等并发症，致残率被致死率较高，糖尿病其并发症给患者、家庭以及社会带来沉重经济和精神负担，糖尿病以及其他慢性非传染性心血管疾病的预防和治疗将成为21世纪医疗卫生事业的主要挑战。
王不留行为石竹科植物麦蓝菜Vaccaria Segetalis(Neck.)Garcke的干燥成熟种子，是一种常见的中药，具有活血通经、下乳消肿等功效。王不留行主要含有刺桐碱、三萜皂苷、黄酮苷、类脂、环肽、脂肪酸和单糖等成分，过去实验室研究发现王不留行黄酮苷具有促进血管新生，加快开放性创伤的愈合速度，对抗高糖和氧化应激的引起的内皮细胞损伤，提示王不留行黄酮苷可能具有心血管保护作用，尤其是目前尚未有报道王不留行黄酮苷在制备抗糖尿病药物中的作用。
发明内容
本发明要解决的是为现有的抗糖尿病药物制备技术领域提供一种新的途径，提供王不留行黄酮苷在抗糖尿病药物中的作用，因此本研究提供的技术方法是将王不留行黄酮苷应用于制备治疗糖尿病的药物。
本发明的有益效果是：王不留行黄酮苷改善糖尿病的血糖和血脂，将王不留行黄酮苷应用到抗糖尿病相关药物的开发中，以制备更好的抗糖尿病的新思路，不仅拓展了抗糖尿病药物的选择，也为我国抗糖尿病中药的筛选提供的新的策略。
附图说明
图1：王不留行黄酮苷对糖尿病小鼠血糖的影响。
图2：王不留行黄酮苷对糖尿病小鼠血清甘油三酯(TG)、总胆固醇(T-CHO)，低密度脂蛋白(LDL)的影响。
图3：王不留行黄酮苷对糖尿病小鼠肝脏病理的影响。
实施例1 2型糖尿病模型小鼠的制备
糖尿病模型小鼠制作方法：参考国内外权威期刊，我们采用链脲霉菌(STZ)联合高脂饮食(HFD)诱导2型糖尿病模型，将6周龄的C57BL/6J小鼠禁食4小时后一次性腹腔注射小剂量STZ(120mg/kg)，正常对照组注射溶媒作为对照。3周后，糖尿病模型组开始给予高脂饮食(21.8kJ/g,脂肪含量60％)直至实验完成，对照组始终给予正常饮食(14.7kJ/g,脂肪含量13％)。
实施例2实验分组及王不留行黄酮苷干预
将6周龄的C57BL/6J小鼠随机分三组：
(1)正常小鼠-生理盐水组：为正常对照组，始终给予正常饮食和饮水，5周后给予生理盐水皮下灌注4周作为王不留行黄酮苷(Vaccarin)的对照；
(2)糖尿病-生理盐水组采用链脲霉菌(STZ)联合高脂饮食(HFD)方法引起糖尿病，5周后给予生理盐水(saline)腹腔注射4周作为王不留行黄酮苷(Vaccarin)的对照；
(3)糖尿病-黄酮苷低剂量组(1mg/kg)：采用链脲霉菌(STZ)联合高脂饮食(HFD)诱导2型糖尿病模型，5周后给予王不留行黄酮苷(Vaccarin)腹腔注射4周。
(4)糖尿病-黄酮苷低剂量组(10mg/kg)：采用链脲霉菌(STZ)联合高脂饮食(HFD)诱导2型糖尿病模型，5周后给予王不留行黄酮苷(Vaccarin)腹腔注射4周。
实施例3空腹血糖测定
测量空腹血糖需将小鼠禁食过夜，第二天用血糖仪经尾静脉采血测定。
实施例4血清脂质代谢指标测定
采用生化分析试剂盒测定血清甘油三酯(TG)、总胆固醇(TCH)和低密度脂蛋白(LDL)。
实施例5肝脏苏木素伊红(HE)染色
戊巴比妥钠麻醉小鼠，打开胸腔、暴露心脏，经左心室插管至升主动脉，夹壁腹主动脉，左心耳剪开一小出口，快速灌注0.01M PBS(37℃)冲洗至流出液清亮后再灌注预冷(4℃)的4％多聚甲醛固定(先快后慢，在大鼠肢体伸展后减慢速度)。取出肝脏，置于4℃的4％多聚甲醛后固定24h，脱水，石蜡包埋，切片，进行常规苏木素伊红(HE)染色。
实验结果如附图1至3中所示：
(1)王不留行黄酮苷(Vaccarin)腹腔注射干预后对空腹血糖水平的影响：
与对照组(Control)相比，模型组(STZ/HFD)C57BL/6小鼠血糖显著升高，而给予不同剂量的王不留行黄酮苷组显著降低血糖升高，详见图1。
数据均以均值±标准差(mean±SD)表示，每组样本为7，P<0.05为有统计学差异，***与Control组相比，P<0.001；$$$与STZ/HFD组相比，P<0.001。Control，对照组；STZ/HFD，高血糖模型组；STZ/HFD-Vaccarin1，给予王不留行黄酮苷的剂量为1mg/kg；STZ/HFD-Vaccarin1，给予王不留行黄酮苷的剂量为10mg/kg。
(2)王不留行黄酮苷(Vaccarin)腹腔注射干预后对血清脂质代谢指标的影响：
与对照组(Control)相比，模型组(STZ/HFD)C57BL/6小鼠的TG、TCH、LDL-C显著升高，而给予不同剂量的王不留行黄酮苷组显著降低上述代谢指标的水平，详见图2。
数据均以均值±标准差(mean±SD)表示，每组样本为7，P<0.05为有统计学差异，***与Control组相比，P<0.001；$$与STZ/HFD组相比，P<0.01；$$$与STZ/HFD组相比，P<0.001。Control，对照组；STZ/HFD，高血糖模型组；STZ/HFD-Vaccarin1，给予王不留行黄酮苷的剂量为1mg/kg；STZ/HFD-Vaccarin1，给予王不留行黄酮苷的剂量为10mg/kg。
(3)王不留行黄酮苷(Vaccarin)腹腔注射干预后对肝脏病理病变的影响：
与对照组(Control)相比，模型组(STZ/HFD)C57BL/6小鼠肝细胞排列紊乱，肝细胞体积增大，密度不均，偶见脂肪变性，而给予不同剂量的王不留行黄酮苷组上述改变均有不同程度的减轻，详见图3。
Claims (2)
1.王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用。
2.根据权利要求1所述，其特征在于王不留行黄酮苷抗糖尿病代谢紊乱应用的产品形式包括保健品、营养品和药物制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710123392.4A CN106668053A (zh) | 2017-03-03 | 2017-03-03 | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710123392.4A CN106668053A (zh) | 2017-03-03 | 2017-03-03 | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668053A true CN106668053A (zh) | 2017-05-17 |
Family
ID=58862571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710123392.4A Pending CN106668053A (zh) | 2017-03-03 | 2017-03-03 | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668053A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791091A (zh) * | 2021-01-15 | 2021-05-14 | 江南大学 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948619A (zh) * | 2014-05-12 | 2014-07-30 | 江南大学 | 一种具有抗氧化抗高糖损伤的王不留行黄酮苷的应用 |
-
2017
- 2017-03-03 CN CN201710123392.4A patent/CN106668053A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948619A (zh) * | 2014-05-12 | 2014-07-30 | 江南大学 | 一种具有抗氧化抗高糖损伤的王不留行黄酮苷的应用 |
Non-Patent Citations (2)
| Title |
|---|
| 王旭 等: "王不留行黄酮苷的分离纯化及对细胞增殖活性的影响", 《天然产物研究与开发》 * |
| 谢凤珊 等: "王不留行黄酮苷对过氧化氢和高糖诱导损伤的人脐静脉内皮细胞的保护作用", 《天然产物研究与开发》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112791091A (zh) * | 2021-01-15 | 2021-05-14 | 江南大学 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
| CN112791091B (zh) * | 2021-01-15 | 2022-04-29 | 江南大学 | 王不留行黄酮苷在改善肠道屏障功能中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102511712A (zh) | 一种含有低聚木糖的辅助降血糖保健食品 | |
| CN107441078A (zh) | 一种治疗糖尿病的药物组合物及其制备方法和用途 | |
| Kassem et al. | Insulin therapy during Ramadan fast for Type 1 diabetes patients | |
| CN102526478A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN101390887A (zh) | 三七总皂苷的药物组合物 | |
| CN105687441A (zh) | 荔枝皮多酚在治疗高血糖及胰岛素抵抗的药物中的应用 | |
| Bi et al. | Comparative study of crude and wine-processing Corni Fructus on chemical composition and antidiabetic effects | |
| CN103585632A (zh) | 胆汁酸螯合剂或/和维生素d在制备防治非酒精性脂肪性肝病药物中的应用 | |
| CN106668053A (zh) | 王不留行黄酮苷在制备抗糖尿病糖脂代谢紊乱药物中的应用 | |
| CN107823286A (zh) | 粘委陵菜提取物及其应用 | |
| CA3022247C (en) | Composition for treating diabetic disease | |
| CN101474346B (zh) | 薤白提取物及其制备方法与应用 | |
| CN106727480B (zh) | Fex-3在制备抗肥胖症药物中的应用 | |
| CN104784192B (zh) | 蚌肉寡糖在制备降血糖药物中的应用及其制备方法 | |
| CN101264203B (zh) | 治疗糖尿病的中西药组合物 | |
| CN109966283A (zh) | 脱脂肉桂多酚提取物在制备防治糖尿病肾病产品中的应用 | |
| CN109806268A (zh) | 哇巴因在制备抗非酒精性脂肪肝药物中的应用 | |
| CN115364142B (zh) | 芪冬颐心口服液在制备治疗糖尿病心肌病的药物中的应用 | |
| CN110123827A (zh) | 一种治疗由代谢异常所致疾病的药物组合物及其制备方法和应用 | |
| CN108079000A (zh) | 一种治疗糖尿病的药物组合物及其制备方法 | |
| CN108175779A (zh) | 黄芪与当归的萃取物用于治疗肺癌及降低抗癌药剂副作用的用途 | |
| CN103330836A (zh) | 一种治疗糖尿病的中药组合物及其应用 | |
| CN100484543C (zh) | 一种治疗肝炎的药物组合物及其制备方法和用途 | |
| TWI698244B (zh) | 小分子褐藻醣膠與藻褐素之組合物用於製備改善非酒精性脂肪肝之組成物的用途 | |
| CN101874830A (zh) | 萸炙黄连炮制品的新用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170517 |